Most growth hormone secretagogues come with baggage. GHRP-6 jacks up cortisol and makes you ravenous. GHRP-2 spikes prolactin. Hexarelin stops working after a few weeks. When Novo Nordisk developed ipamorelin in the late 1990s, they set out to fix exactly that — and the published data suggests they pulled it off.
Ipamorelin triggers growth hormone release without touching cortisol, prolactin, or appetite. That selectivity is why it’s become one of the most studied GH secretagogues in the research community.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
What Made Ipamorelin Different From Day One
The landmark 1998 paper by Raun et al. in the European Journal of Endocrinology told the story in one clean comparison. They lined up ipamorelin against GHRP-6, GHRP-2, and native GHRH, then measured everything the pituitary spit out:
- Growth Hormone: Dose-dependent release, comparable to GHRP-6 ✓
- ACTH/Cortisol: No significant change (GHRP-6 elevated both) ✓
- Prolactin: No significant change (GHRP-2 elevated it) ✓
- Aldosterone, FSH, LH: Flat. No change. ✓
Same GH output, none of the hormonal side noise. For researchers trying to study GH-specific effects, this was a game changer — no more untangling cortisol confounders from actual GH-mediated results.
Reference: Raun K, et al. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
How It Works: The GHS-R1a Pathway
Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a) — the same receptor that ghrelin, your body’s hunger hormone, naturally targets. But where ghrelin triggers appetite, cortisol release, and a cascade of other effects, ipamorelin hits the GH-release button and leaves the rest alone.
Mechanistically, GHS-R1a activation triggers a phospholipase C → IP3 → calcium signaling cascade in pituitary somatotroph cells, resulting in GH release. This is a completely separate pathway from how GHRH works (which signals through cAMP/PKA via a different receptor). That independence is why researchers often combine ipamorelin with GHRH analogs like CJC-1295 — two separate levers pulling in the same direction.
What Researchers Have Found
It Preserves Natural GH Pulsing
Your body doesn’t release growth hormone in a steady drip — it comes in bursts (pulses) throughout the day, with the biggest spikes during deep sleep. That pulsatile pattern matters. Constant GH exposure produces different biological effects than natural pulses.
Hansen et al. (2001) studied ipamorelin in swine and found something important: it amplified the natural pulse pattern rather than overriding it with artificial sustained elevation. The body’s own rhythm stayed intact — ipamorelin just turned up the volume on each pulse.
Bone Gets Stronger
Growth hormone drives bone formation through IGF-1. Svensson et al. (2000) tested GH secretagogues including ipamorelin in ovariectomized rats (the standard model for bone loss research) and found increased bone formation markers and higher bone mineral density. Johansen et al. (2003) went further — looking at actual fracture healing — and reported increased mineral content and larger callus formation at fracture sites in treated animals.
Your Gut Listens Too
Here’s a research direction most people don’t expect: GHS-R1a receptors are scattered throughout the GI tract (ghrelin is a gut hormone, after all). Greenwood-Van Meerveld et al. (2012) found that ipamorelin accelerated gastric emptying and colonic transit in rodent models. This led to clinical-stage investigation for post-surgical GI recovery — one of the few times a GH secretagogue was studied for a non-endocrine use.
The GH Secretagogue Comparison Chart
How does ipamorelin stack up against the competition?
- GHRP-6: Strong GH release, but also spikes cortisol, ACTH, prolactin, and appetite. Hard to isolate GH effects in research.
- GHRP-2: Better than GHRP-6 on appetite, but still elevates prolactin and cortisol at higher doses.
- Hexarelin: Most potent GHS available, but desensitizes rapidly (tachyphylaxis) — GH response drops with repeated dosing.
- Ipamorelin: Matches GHRP-6 on GH output. No cortisol, prolactin, or appetite effects. No desensitization in sustained studies. The cleanest profile of the bunch.
The CJC-1295 + Ipamorelin Stack
This is the most commonly studied GH secretagogue combination, and the logic is straightforward: GHRH analogs like sermorelin or CJC-1295 amplify pulse amplitude (bigger bursts), while ipamorelin increases pulse frequency (more bursts). Different pathways, synergistic output. Studies show the combination produces GH responses exceeding what either compound achieves alone.
Product Specifications
- Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- Molecular Weight: 711.85 g/mol
- CAS Number: 170851-70-4
- Physical Form: Sterile lyophilized white powder
- Purity: ≥99% (verified by HPLC)
- Solubility: Freely soluble in bacteriostatic water
Key References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
- Hansen BS, et al. Effect of ipamorelin on growth hormone release in swine. J Pharmacol Exp Ther. 2001;296(3):1011-1018.
- Svensson J, et al. Growth hormone secretagogues and bone. J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1437-1441.
- Johansen PB, et al. Ipamorelin and bone. Bone. 2003;32(Suppl):S122.
- Greenwood-Van Meerveld B, et al. Ipamorelin augments gastrointestinal motility. Eur J Pharmacol. 2012.
All compounds at Chameleon Peptides are independently tested at Janoshik Analytical. Browse Ipamorelin or explore related GH research peptides like CJC-1295 + Ipamorelin, Sermorelin, and Tesamorelin.